[Expert recommendation: treatment of nonambulatory patients with Duchenne muscular dystrophy].
Sign Up to like & getrecommendations! Published in 2020 at "Der Nervenarzt"
DOI: 10.1007/s00115-020-01019-3
Abstract: BACKGROUND Duchenne muscular dystrophy (DMD) is the most frequent genetic neuromuscular disease in childhood with loss of ambulation usually occurring around the age of 9-11 years. OBJECTIVE, MATERIAL AND METHODS Based on current guidelines and clinical… read more here.
Keywords: dmd patients; ambulation; treatment; disease ... See more keywords
High urinary ferritin reflects myoglobin iron evacuation in DMD patients
Sign Up to like & getrecommendations! Published in 2018 at "Neuromuscular Disorders"
DOI: 10.1016/j.nmd.2018.03.008
Abstract: Duchenne muscular dystrophy (DMD) is an X-linked disease caused by mutations in the dystrophin gene leading to the absence of the normal dystrophin protein. The efforts of many laboratories brought new treatments of DMD to… read more here.
Keywords: dmd; dmd patients; high urinary; urinary ferritin ... See more keywords
Safety issues and harmful pharmacological interactions of nutritional supplements in Duchenne muscular dystrophy: considerations for Standard of Care and emerging virus outbreaks
Sign Up to like & getrecommendations! Published in 2020 at "Pharmacological Research"
DOI: 10.1016/j.phrs.2020.104917
Abstract: Abstract At the moment, little treatment options are available for Duchenne muscular dystrophy (DMD). The absence of the dystrophin protein leads to a complex cascade of pathogenic events in myofibres, including chronic inflammation and oxidative… read more here.
Keywords: dmd patients; muscular dystrophy; safety issues; issues harmful ... See more keywords